NAD Refers Advertising For Solace “Dermatend Mole, Wart & Skintag Remover” To FTC For Further Review

New York, New York – Nov. 8,   2011 – The National Advertising Division of the Council of Better Business Bureaus has referred advertising by Solace International, Inc. to the Federal Trade Commission for further review following the company’s decision not to participate in an NAD proceeding.

As part of its routine monitoring program, NAD requested substantiation for certain performance and implied claims made in print advertising by Solace for the company’s DermaTend Mole Wart & Skin Tag Remover, including:

  • “Removes unwanted moles, warts and skin tags!”
  • “Unlike surgery, you won’t be left with unsightly scars and or a large doctor bill.”
  • “DermaTend permanently removes all unwanted moles, warts and skin tags quickly and easily.”
  • Applying DermaTend is just as effective as surgery when removing moles, warts and skin tags.

In response to NAD’s inquiry, the advertiser said that while it denied any misleading or improper advertising, it would voluntarily remove references to surgery or doctor bills from its advertising. The advertiser further noted that it declined to participate in the self-regulatory forum. 

While NAD noted its appreciation of the advertiser’s representation, such action did not resolve the remaining challenged claims. 

In light of the advertiser’s position and pursuant to NAD procedures, the advertising at issue has been referred to the FTC for further review.